1. Present status of bone marrow transplantation in Japan.
- Author
-
Masaoka T, Shibata H, Nakamura H, and Inoue T
- Subjects
- Acute Disease, Cyclosporins therapeutic use, Graft vs Host Disease complications, Graft vs Host Disease drug therapy, Humans, Japan, Leukemia drug therapy, Leukemia mortality, Methotrexate therapeutic use, Methotrexate toxicity, Transplantation, Autologous, Transplantation, Homologous, Transplantation, Isogeneic, Bone Marrow Transplantation, Leukemia therapy
- Abstract
One hundred and seventy three bone marrow transplantations (BMT) including 133 allogeneic, 17 syngeneic and 23 autologous BMT were recorded in Japan during the period between September, 1975 and March, 1984. The number of cases of BMT increased rapidly over the years, i.e., 16 cases in 1980, 27 in 1981, 39 in 1982 and 57 in 1983. All cases were treated in clean rooms, many of them receiving intensive gut decontamination containing vancomycin. In 110 cases with acute leukemia, the main causes of death were interstitial pneumonitis, relapse of leukemia, infection and GvHD. Favorable factors determined from 180-day survival were remission, no infection, low dose rate and fractionated total body irradiation (TBI), ABO minor mismatch and positive graft versus host reaction. Long-term survival of patients who received BMT during remission and were without infection amounted to 70% of acute lymphocytic leukemia (ALL) and 40% of acute myelogenous leukemia (AML) patients. Cyclosporin A (Cy-A) administered in 21 cases was compared with methotrexate (MTX) given in 20 cases. A statistically significant decrease of stomatitis was observed, while no difference in GvHD or survival was seen. There were seven cases giving a more than good response out of 11 cases treated with cyclosporin because methotrexate or immuran was ineffective or could not be administered due to toxicity. Such data suggest that allogeneic BMT is acceptable as a very promising form of treatment for acute leukemia in Japan.
- Published
- 1985